Candriam Luxembourg S.C.A. continued to hold its position in RedHill Biopharma Ltd. (NASDAQ:RDHL) during the second quarter, Holdings Channel reports. The firm owned 71,267 shares of the company’s stock at the end of the second quarter. Candriam Luxembourg S.C.A.’s holdings in RedHill Biopharma were worth $778,000 at the end of the most recent quarter.
Separately, Royal Bank of Canada boosted its position in RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares in the last quarter. 15.30% of the stock is owned by hedge funds and other institutional investors.
RedHill Biopharma Ltd. (NASDAQ:RDHL) remained flat at $13.79 during midday trading on Friday. The stock had a trading volume of 36,547 shares. The firm has a 50 day moving average of $14.70 and a 200 day moving average of $12.76. RedHill Biopharma Ltd. has a 12-month low of $8.10 and a 12-month high of $16.54. The firm’s market cap is $175.60 million.
RedHill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings results on Wednesday, July 27th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.52. On average, equities research analysts anticipate that RedHill Biopharma Ltd. will post ($2.06) EPS for the current year.
RDHL has been the topic of a number of recent analyst reports. HC Wainwright set a $33.00 target price on RedHill Biopharma and gave the stock a “buy” rating in a report on Friday. FBR & Co restated a “buy” rating on shares of RedHill Biopharma in a report on Thursday. Finally, Zacks Investment Research upgraded RedHill Biopharma from a “sell” rating to a “hold” rating in a report on Wednesday, September 28th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $26.20.
About RedHill Biopharma
Want to see what other hedge funds are holding RDHL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RedHill Biopharma Ltd. (NASDAQ:RDHL).
Receive News & Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.